| Literature DB >> 21108977 |
Christian Kemmer1, David Andreas Fluri, Ulrich Witschi, Alain Passeraub, Andreas Gutzwiller, Martin Fussenegger.
Abstract
Synthetic biology has been successfully used to program novel metabolic function in mammalian cells and to design the first-generation of prosthetic networks that have shown the potential for the treatment of obesity, hormone-related disorders and hyperuricemia in small-animal model systems. By functionally rewiring luteinizing hormone receptor signaling to CREB1 (cAMP-responsive element binding protein 1)-mediated transgene expression via the common cyclic adenosine monophosphate (cAMP) second messenger pool we have designed an artificial insemination device which enables lutropin-triggered in-utero release of sperms protected inside cellulose-based implants. Swiss dairy cows treated with such in-utero implants containing spermatozoa and mammalian cells transgenic for luteinizing hormone receptor and CREB1-inducible expression of an engineered cellulase showed ovulation-triggered implant degradation and sperm release leading to successful fertilization of the animals. Synthetic devices plugged into endogenous control circuitry enable the body to automatically control spatio-temporal metabolic activities that could improve the economics of cattle breeding and provide novel opportunities for future therapeutic interventions.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21108977 DOI: 10.1016/j.jconrel.2010.11.016
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776